Health Care & Life Sciences » Pharmaceuticals | BAFNA Pharmaceuticals Ltd.

BAFNA Pharmaceuticals Ltd. | Balance Sheet

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
28
28
27
27
30
27
Total Accounts Receivable
1,036
897
822
549
243
248
Inventories
421
260
292
358
107
93
Other Current Assets
80
86
81
189
108
116
Total Current Assets
1,565
1,271
1,223
1,122
487
485
Net Property, Plant & Equipment
534
545
526
486
449
370
Total Investments and Advances
-
169
169
169
442
330
Intangible Assets
-
-
-
-
159
-
Other Assets
101
13
9
11
13
10
Total Assets
2,358
1,998
1,927
1,789
1,391
1,195
ST Debt & Current Portion LT Debt
853
570
453
434
233
Accounts Payable
418
422
377
239
286
Income Tax Payable
5
23
24
26
-
Other Current Liabilities
78
95
96
116
79
Total Current Liabilities
1,354
1,111
950
815
598
Long-Term Debt
242
116
352
390
232
Deferred Taxes
64
40
38
29
51
Other Liabilities
-
4
9
128
130
Total Liabilities
1,661
1,271
1,350
1,362
1,012
Common Equity (Total)
689
718
578
427
379
Total Shareholders' Equity
689
718
578
427
379
Total Equity
697
727
578
427
379
Liabilities & Shareholders' Equity
2,358
1,998
1,927
1,789
1,391
Accumulated Minority Interest
9
9
-
-
-

About BAFNA Pharmaceuticals

View Profile
Address
Bafna Towers
Chennai Tamil Nadu 600001
India
Employees -
Website http://www.bafnapharma.com
Updated 07/08/2019
Bafna Pharmaceuticals Ltd. is engaged in the manufacture of drugs and medicines of life saving drugs. Its brand portfolio includes Raricap, Raricap Forte, Raricap L Suspension and Raricap Combi. The company was founded in 1981 and is headquartered in Chennai, India.